These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

513 related articles for article (PubMed ID: 19407038)

  • 1. Paying a high price for low costs: why there should be no legal constraints on the profits that can be made on drugs for tropical diseases.
    Sonderholm J
    J Med Ethics; 2009 May; 35(5):315-9. PubMed ID: 19407038
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Philippines joins other developing countries in limiting prices of drugs.
    Bland B
    BMJ; 2009 Aug; 339():b3151. PubMed ID: 19651688
    [No Abstract]   [Full Text] [Related]  

  • 3. Examining the link between price regulation and pharmaceutical R&D investment.
    Vernon JA
    Health Econ; 2005 Jan; 14(1):1-16. PubMed ID: 15386673
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Are rich nations up for drug reform?
    Check E
    Nature; 2006 May; 441(7090):135. PubMed ID: 16688137
    [No Abstract]   [Full Text] [Related]  

  • 5. Reprivatizing pharmaceutical supplies in Africa.
    Turshen M
    J Public Health Policy; 2001; 22(2):198-225. PubMed ID: 11469153
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmaceutical companies' variation of drug prices within and among countries can improve long-term social well-being.
    Lichtenberg FR
    Health Aff (Millwood); 2011 Aug; 30(8):1539-44. PubMed ID: 21821571
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ethical issues in funding research and development of drugs for neglected tropical diseases.
    Oprea L; Braunack-Mayer A; Gericke CA
    J Med Ethics; 2009 May; 35(5):310-4. PubMed ID: 19407037
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Eliminating neglected diseases in poor countries: a conversation with Andrew Witty. Interview by Susan Dentzer.
    Witty A
    Health Aff (Millwood); 2009; 28(3):w411-6. PubMed ID: 19299425
    [No Abstract]   [Full Text] [Related]  

  • 9. How can states provide affordable pharmaceuticals to the underserved?
    Zara J
    J Health Care Poor Underserved; 2006 Nov; 17(4):808-20. PubMed ID: 17242532
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Orphan drug legislation: lessons for neglected tropical diseases.
    Villa S; Compagni A; Reich MR
    Int J Health Plann Manage; 2009; 24(1):27-42. PubMed ID: 18435430
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Early benefit assessment for pharmaceuticals in Germany: lessons for policymakers.
    Schlette S; Hess R
    Issue Brief (Commonw Fund); 2013 Oct; 29():1-9. PubMed ID: 24171232
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Finding cures for tropical diseases: is open source an answer?
    Maurer SM; Rai A; Sali A
    PLoS Med; 2004 Dec; 1(3):e56. PubMed ID: 15630466
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drug companies and third world: a case study in neglect. Medicine merchants: a special report.
    McNeil DG
    N Y Times Web; 2000 May; ():A1,6. PubMed ID: 11873794
    [No Abstract]   [Full Text] [Related]  

  • 14. Drug price deal spells windfall for researchers.
    Bosch X
    Nature; 2001 Nov; 414(6860):138. PubMed ID: 11700514
    [No Abstract]   [Full Text] [Related]  

  • 15. TRIPS, pharmaceuticals, developing countries, and the Doha "solution".
    Sykes AO
    Chic J Int Law; 2002; 3(1):47-68. PubMed ID: 15709299
    [No Abstract]   [Full Text] [Related]  

  • 16. Public-private partnership: from there to here.
    Croft SL
    Trans R Soc Trop Med Hyg; 2005 Oct; 99 Suppl 1():S9-14. PubMed ID: 16087204
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Priority setting and the 'neglected' tropical diseases.
    Canning D
    Trans R Soc Trop Med Hyg; 2006 Jun; 100(6):499-504. PubMed ID: 16540135
    [TBL] [Abstract][Full Text] [Related]  

  • 18. EU launches measures to stop diversion of cut-price drugs.
    Fleck F
    Bull World Health Organ; 2003; 81(7):549. PubMed ID: 12973652
    [No Abstract]   [Full Text] [Related]  

  • 19. Retail price regulation and innovation: reference pricing in the pharmaceutical industry.
    Bardey D; Bommier A; Jullien B
    J Health Econ; 2010 Mar; 29(2):303-16. PubMed ID: 20053474
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Public-private partnerships: new ways to discover, develop and deliver drugs for tropical diseases.
    Hentschel CC
    Southeast Asian J Trop Med Public Health; 2004; 35 Suppl 2():1-4. PubMed ID: 15906625
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 26.